Literature DB >> 34140396

Comprehensive Search for Novel Circulating miRNAs and Axon Guidance Pathway Proteins Associated with Risk of ESKD in Diabetes.

Eiichiro Satake1,2, Pierre-Jean Saulnier3,4, Hiroki Kobayashi1,2, Manoj K Gupta1,2, Helen C Looker3, Jonathan M Wilson5, Zaipul I Md Dom1,2, Katsuhito Ihara1,2, Kristina O'Neil1,2, Bozena Krolewski1,2, Caterina Pipino1,2,6, Meda E Pavkov7, Viji Nair8, Markus Bitzer8, Monika A Niewczas1,2, Matthias Kretzler8, Michael Mauer9, Alessandro Doria1,2, Behzad Najafian10, Rohit N Kulkarni1,2, Kevin L Duffin5, Marcus G Pezzolesi1,2,11, C Ronald Kahn1,2, Robert G Nelson12, Andrzej S Krolewski1,2.   

Abstract

BACKGROUND: Mechanisms underlying the pro gression of diabetic kidney disease to ESKD are not fully understood.
METHODS: We performed global microRNA (miRNA) analysis on plasma from two cohorts consisting of 375 individuals with type 1 and type 2 diabetes with late diabetic kidney disease, and targeted proteomics analysis on plasma from four cohorts consisting of 746 individuals with late and early diabetic kidney disease. We examined structural lesions in kidney biopsy specimens from the 105 individuals with early diabetic kidney disease. Human umbilical vein endothelial cells were used to assess the effects of miRNA mimics or inhibitors on regulation of candidate proteins.
RESULTS: In the late diabetic kidney disease cohorts, we identified 17 circulating miRNAs, represented by four exemplars (miR-1287-5p, miR-197-5p, miR-339-5p, and miR-328-3p), that were strongly associated with 10-year risk of ESKD. These miRNAs targeted proteins in the axon guidance pathway. Circulating levels of six of these proteins-most notably, EFNA4 and EPHA2-were strongly associated with 10-year risk of ESKD in all cohorts. Furthermore, circulating levels of these proteins correlated with severity of structural lesions in kidney biopsy specimens. In contrast, expression levels of genes encoding these proteins had no apparent effects on the lesions. In in vitro experiments, mimics of miR-1287-5p and miR-197-5p and inhibitors of miR-339-5p and miR-328-3p upregulated concentrations of EPHA2 in either cell lysate, supernatant, or both.
CONCLUSIONS: This study reveals novel mechanisms involved in progression to ESKD and points to the importance of systemic factors in the development of diabetic kidney disease. Some circulating miRNAs and axon guidance pathway proteins represent potential targets for new therapies to prevent and treat this condition.
Copyright © 2021 by the American Society of Nephrology.

Entities:  

Keywords:  chronic kidney disease; diabetic nephropathy; end stage kidney disease; progression of renal failure

Mesh:

Substances:

Year:  2021        PMID: 34140396      PMCID: PMC8729832          DOI: 10.1681/ASN.2021010105

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   14.978


  73 in total

1.  MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells.

Authors:  Margaret S Ebert; Joel R Neilson; Phillip A Sharp
Journal:  Nat Methods       Date:  2007-08-12       Impact factor: 28.547

Review 2.  Extracellular miRNAs: From Biomarkers to Mediators of Physiology and Disease.

Authors:  Marcelo A Mori; Raissa G Ludwig; Ruben Garcia-Martin; Bruna B Brandão; C Ronald Kahn
Journal:  Cell Metab       Date:  2019-08-22       Impact factor: 27.287

3.  Eph family receptors and ligands in vascular cell targeting and assembly.

Authors:  E Stein; H Schoecklmann; T O Daniel
Journal:  Trends Cardiovasc Med       Date:  1997-11       Impact factor: 6.677

Review 4.  Involvement of small Ras GTPases and their effectors in chronic renal disease.

Authors:  C Martínez-Salgado; A B Rodríguez-Peña; J M López-Novoa
Journal:  Cell Mol Life Sci       Date:  2008-02       Impact factor: 9.261

Review 5.  Eph/ephrin signaling in epithelial development and homeostasis.

Authors:  Hui Miao; Bingcheng Wang
Journal:  Int J Biochem Cell Biol       Date:  2008-08-09       Impact factor: 5.085

6.  Effects of intensive glucose lowering in type 2 diabetes.

Authors:  Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

7.  Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability.

Authors:  Erika Assarsson; Martin Lundberg; Göran Holmquist; Johan Björkesten; Stine Bucht Thorsen; Daniel Ekman; Anna Eriksson; Emma Rennel Dickens; Sandra Ohlsson; Gabriella Edfeldt; Ann-Catrin Andersson; Patrik Lindstedt; Jan Stenvang; Mats Gullberg; Simon Fredriksson
Journal:  PLoS One       Date:  2014-04-22       Impact factor: 3.240

8.  voom: Precision weights unlock linear model analysis tools for RNA-seq read counts.

Authors:  Charity W Law; Yunshun Chen; Wei Shi; Gordon K Smyth
Journal:  Genome Biol       Date:  2014-02-03       Impact factor: 13.583

9.  Adipose-derived circulating miRNAs regulate gene expression in other tissues.

Authors:  Thomas Thomou; Marcelo A Mori; Jonathan M Dreyfuss; Masahiro Konishi; Masaji Sakaguchi; Christian Wolfrum; Tata Nageswara Rao; Jonathon N Winnay; Ruben Garcia-Martin; Steven K Grinspoon; Phillip Gorden; C Ronald Kahn
Journal:  Nature       Date:  2017-02-15       Impact factor: 49.962

10.  MicroRNA-328 inhibits renal tubular cell epithelial-to-mesenchymal transition by targeting the CD44 in pressure-induced renal fibrosis.

Authors:  Cheng-Hsien Chen; Chung-Yi Cheng; Yen-Cheng Chen; Yuh-Mou Sue; Chung-Te Liu; Tzu-Hurng Cheng; Yung-Ho Hsu; Tso-Hsiao Chen
Journal:  PLoS One       Date:  2014-06-11       Impact factor: 3.240

View more
  6 in total

1.  Neuroblastoma suppressor of tumorigenicity 1 is a circulating protein associated with progression to end-stage kidney disease in diabetes.

Authors:  Hiroki Kobayashi; Helen C Looker; Eiichiro Satake; Francesca D'Addio; Jonathan M Wilson; Pierre Jean Saulnier; Zaipul I Md Dom; Kristina O'Neil; Katsuhito Ihara; Bozena Krolewski; Hannah S Badger; Adriana Petrazzuolo; Domenico Corradi; Andrzej Galecki; Parker C Wilson; Behzad Najafian; Michael Mauer; Monika A Niewczas; Alessandro Doria; Benjamin D Humphreys; Kevin L Duffin; Paolo Fiorina; Robert G Nelson; Andrzej S Krolewski
Journal:  Sci Transl Med       Date:  2022-08-10       Impact factor: 19.319

2.  Predictors of Kidney Disease Progression in Diabetes and Precision Medicine: Something Old, Something New, and Something Borrowed.

Authors:  George Vasquez-Rios; Steven G Coca
Journal:  J Am Soc Nephrol       Date:  2021-09       Impact factor: 14.978

3.  The Next Frontier: Biomarkers and Artificial Intelligence Predicting Cardiorenal Outcomes in Diabetic Kidney Disease.

Authors:  Gregory L Braden; Daniel L Landry
Journal:  Kidney360       Date:  2022-09-29

4.  Results of untargeted analysis using the SOMAscan proteomics platform indicates novel associations of circulating proteins with risk of progression to kidney failure in diabetes.

Authors:  Hiroki Kobayashi; Helen C Looker; Eiichiro Satake; Pierre Jean Saulnier; Zaipul I Md Dom; Kristina O'Neil; Katsuhito Ihara; Bozena Krolewski; Andrzej T Galecki; Monika A Niewczas; Jonathan M Wilson; Alessandro Doria; Kevin L Duffin; Robert G Nelson; Andrzej S Krolewski
Journal:  Kidney Int       Date:  2022-05-23       Impact factor: 18.998

5.  The Non-Coding RNA Journal Club: Highlights on Recent Papers-10.

Authors:  Jairo A Pinzon Cortes; Assam El-Osta; Giulia Fontemaggi; Nicholas Delihas; Katsuki Miyazaki; Ajay Goel; Mira Brazane; Clément Carré; Paola Dama; Salih Bayraktar; Leandro Castellano; Francisco J Enguita; Tijana Mitic; Andrea Caporali; André P Gerber; Nicola Amodio
Journal:  Noncoding RNA       Date:  2022-01-10

6.  Icariin and Competing Endogenous RNA Network: A Potential Protective Strategy Against Contrast-Induced Acute Kidney Injury.

Authors:  Yan Lin; Gaofeng Zhu; Xiaoyong Li; Huaxiao Yu; Yuhang Luo; Jiaqiong Lin; Renyuan Li; Zena Huang
Journal:  Drug Des Devel Ther       Date:  2022-07-23       Impact factor: 4.319

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.